GEAP202416581A - Vegf and tie2-binding fusion protein and uses thereof - Google Patents

Vegf and tie2-binding fusion protein and uses thereof

Info

Publication number
GEAP202416581A
GEAP202416581A GEAP202416581A GEAP2024016581A GEAP202416581A GE AP202416581 A GEAP202416581 A GE AP202416581A GE AP202416581 A GEAP202416581 A GE AP202416581A GE AP2024016581 A GEAP2024016581 A GE AP2024016581A GE AP202416581 A GEAP202416581 A GE AP202416581A
Authority
GE
Georgia
Prior art keywords
fusion protein
vegf
tie2
binding fusion
vascular
Prior art date
Application number
GEAP202416581A
Other languages
English (en)
Georgian (ka)
Inventor
Kwangsoo Kim
Philip Durost
Minkyung Choo
Sangyeul Han
Original Assignee
Ingenia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ingenia Therapeutics Inc filed Critical Ingenia Therapeutics Inc
Publication of GEAP202416581A publication Critical patent/GEAP202416581A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GEAP202416581A 2022-01-13 2023-01-12 Vegf and tie2-binding fusion protein and uses thereof GEAP202416581A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263299177P 2022-01-13 2022-01-13
US202263310359P 2022-02-15 2022-02-15
US202263335805P 2022-04-28 2022-04-28

Publications (1)

Publication Number Publication Date
GEAP202416581A true GEAP202416581A (en) 2024-12-10

Family

ID=87279731

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP202416581A GEAP202416581A (en) 2022-01-13 2023-01-12 Vegf and tie2-binding fusion protein and uses thereof

Country Status (16)

Country Link
US (1) US20230287109A1 (cg-RX-API-DMAC7.html)
EP (1) EP4463482A4 (cg-RX-API-DMAC7.html)
JP (1) JP7884072B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250005053A (cg-RX-API-DMAC7.html)
AU (1) AU2023206363A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242904A1 (cg-RX-API-DMAC7.html)
CL (2) CL2024002106A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024010934A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240342A (cg-RX-API-DMAC7.html)
DO (1) DOP2024000136A (cg-RX-API-DMAC7.html)
GE (1) GEAP202416581A (cg-RX-API-DMAC7.html)
IL (1) IL314219A (cg-RX-API-DMAC7.html)
JO (1) JOP20240158A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024008737A (cg-RX-API-DMAC7.html)
PE (1) PE20260003A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023137395A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250128899A (ko) * 2024-02-20 2025-08-28 주식회사 맵틱스 Tie2 및 VEGF에 특이적으로 결합하는 이중 특이적 항체 및 이의 용도
WO2026036282A1 (en) * 2024-08-13 2026-02-19 Pentavision Biosciences Limited Multispecific fusion proteins targeting angiogenic factors
US20260226178A1 (en) * 2024-12-23 2026-08-06 Ingenia Therapeutics, Inc. Fusion Proteins Comprising a Tie2 Binding Domain

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3415533A1 (en) * 2011-08-19 2018-12-19 Regeneron Pharmaceuticals, Inc. Anti-tie2 antibodies uses thereof
JP2020501508A (ja) * 2016-09-15 2020-01-23 クアドルセプト バイオ リミテッド 多量体、四量体および八量体
JP2021507723A (ja) * 2017-12-05 2021-02-25 ユニバーシティ オブ ワシントンUniversity of Washington 視細胞における治療遺伝子の機能的発現を増強するための組成物および方法
WO2019235856A1 (ko) * 2018-06-07 2019-12-12 기초과학연구원 Tie2에 결합하는 항체 및 이의 용도
EP3805265A4 (en) * 2018-06-07 2022-07-06 Institute for Basic Science ANTIBODIES BINDING TO TIE2 AND USES THEREOF
JP2021529557A (ja) * 2018-06-29 2021-11-04 ジェンサン バイオファーマ、 インコーポレイテッドGensun Biopharma, Inc. 抗腫瘍免疫チェックポイント調節因子アンタゴニスト
JP7249060B2 (ja) * 2018-08-17 2023-03-30 トリカン・バイオテクノロジー・カンパニー・リミテッド 抗血管新生融合タンパク質およびその使用
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES AGAINST HPTP - BETA (VE-PTP) AND VEGF
AU2020385991A1 (en) * 2019-11-21 2022-06-23 Unity Biotechnology Antibodies directed to Tie-2 and methods of use
CA3169967A1 (en) * 2020-03-24 2021-09-30 Genentech, Inc. Tie2-binding agents and methods of use

Also Published As

Publication number Publication date
IL314219A (en) 2024-09-01
KR20250005053A (ko) 2025-01-09
JP7884072B2 (ja) 2026-07-02
WO2023137395A1 (en) 2023-07-20
DOP2024000136A (es) 2024-10-15
AU2023206363A1 (en) 2024-08-15
CL2025002473A1 (es) 2025-11-14
MX2024008737A (es) 2024-09-11
US20230287109A1 (en) 2023-09-14
JOP20240158A1 (ar) 2024-07-14
CA3242904A1 (en) 2025-03-14
JP2025503704A (ja) 2025-02-04
EP4463482A1 (en) 2024-11-20
CL2024002106A1 (es) 2025-03-28
EP4463482A4 (en) 2026-05-06
CR20240342A (es) 2024-09-18
PE20260003A1 (es) 2026-01-06
CO2024010934A2 (es) 2024-10-31

Similar Documents

Publication Publication Date Title
JOP20240158A1 (ar) بروتين اندماج مرتبط بـ vegf و tie2 واستخداماته
Bogatkevich et al. Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts
BR112023016574A2 (pt) Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão
CR20200100A (es) Conjugado de anticuerpo monoclonal contra bcma -fármaco
PE20191758A1 (es) Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
JOP20240198A1 (ar) أنظمة مضادة لـ vegf ممتدة عالية الجرعة لعلاج اضطرابات وعائية المنشأ بالعين
JOP20230234A1 (ar) أجسام مضادة لـ il-2r مؤازرة وطرق استخدامها
WO2019030762A3 (en) CANNABIS AND ITS DERIVATIVES FOR THE TREATMENT OF PAIN RELATED TO PAIN AND BONE REGENERATION ASSOCIATED WITH BONE DEFECTS IN THE JAW
PE20091029A1 (es) Anticuerpos anti-alfa 5 beta 1
BR112022009273A2 (pt) Imunoglobulinas modificadas para direcionar depósitos amiloides
AR068532A1 (es) Inhibicion de angiogenesis
MX2022002366A (es) Tratamiento de la retinopatía diabética con fab anti-vegf completamente humano modificado postraduccionalmente.
PE20240142A1 (es) Anticuerpos inhibidores via del factor tisular y usos de los mismos
CY1124238T1 (el) Χρηση αντισωματων κατα της σκληροστινης στη θεραπεια της ατελους οστεογενεσης
UA130540C2 (uk) Композиція антитіла b7-h4
JOP20240202A1 (ar) أنظمة ممتدة وعالية الجرعة من مضاد vegf لعلاج اضطرابات العين الوعائية
MA67288A1 (fr) Tubulysines et conjugués tubulysines-protéines
MX2021004045A (es) Metodos para tratar cancer con una combinacion de un anticuerpo anti factor de crecimiento endotelial vascular (vegf) y un conjugado de anticuerpo anti factor tisular-farmaco.
EA202190057A1 (ru) Солюбилизированные апиразы, способы и применение
EA202190807A1 (ru) Антитела к синуклеину
MX2023013207A (es) Anticuerpo agonista anti-pd-1 humano para tratar o prevenir enfermedades inflamatorias, y composicion farmaceutica que contiene el mismo.
CL2025003893A1 (es) Anticuerpo monoclonal que se une a al menos 3 tipos de fibrillas amiloides
AR121441A1 (es) Anticuerpos anti-axl y composiciones
CL2023001268A1 (es) Composiciones farmacéuticas de un inhibidor de cinasa
BR112023000747A2 (pt) Composições para o tratamento de obesidade